Syndax Pharmaceuticals reports combined Q2 sales of $115 million for Revuforj and Niktimvo, annualizing above $200 million each.
Syndax Pharmaceuticals posted combined second-quarter sales of $115 million for its drugs Revuforj and Niktimvo. CEO Michael Metzger noted both treatments are now annualizing at over $200 million each, signaling strong momentum ahead of Q4 axatilimab readouts.
The company previously guided for peak U.S. net revenue of Revuforj to exceed $2 billion. Q2 performance reflects accelerating adoption of both therapies, with management highlighting robust demand trends.
No immediate market reaction was disclosed in the earnings call summary.